Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate.

Bulkmans, N. W. J.; BULK, Saskia; Ottevanger, M. S.; Rozendaal, L.; Hellenberg, S. M.; van Kemenade, F. J.; Snijders, P. J. F.; Boeke, A. J. P.; Meijer, C. J. L. M.

doi:10.1136/jcp.2005.031690

Article (Scientific journals)

Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate.

Bulkmans, N. W. J.; BULK, Saskia; Ottevanger, M. S. et al.

2006 • In Journal of Clinical Pathology, 59 (11), p. 1218-20

Peer Reviewed verified by ORBi

Permalink
https://hdl.handle.net/2268/181848

DOI
10.1136/jcp.2005.031690

PubMed
16943223

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

Bulk 10.pdf

Publisher postprint (166.85 kB)

Request a copy

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Adult; Female; Humans; Mass Screening/methods; Middle Aged; Netherlands; Papillomaviridae/isolation & purification; Papillomavirus Infections/complications/diagnosis; Patient Acceptance of Health Care/statistics & numerical data; Patient Education as Topic; Uterine Cervical Neoplasms/diagnosis/virology; Vaginal Smears

Abstract :

[en] Adding high-risk human papillomavirus (hrHPV) testing to screening increases the efficacy of cervical screening programmes. However, hrHPV testing may result in a lower participation rate because of the perceived association with sexually transmitted infections. We describe how testing for hrHPV was added to cervical screening in the POpulation-BAsed SCreening study AMsterdam (POBASCAM) trial. Participation rates of the screening programme before and after hrHPV implementation were evaluated in the region where the POBASCAM trial was carried out. The participation rate was 58.7% before and 61.4% after the addition of hrHPV testing to screening (p<0.001). An inventory of frequently asked questions is presented. Thus, hrHPV testing can be added to cervical screening by cytology without a decrease in participation rate.

Disciplines :

Genetics & genetic processes

Author, co-author :

Bulkmans, N. W. J.

BULK, Saskia ; Centre Hospitalier Universitaire de Liège - CHU > Génétique

Ottevanger, M. S.

Rozendaal, L.

Hellenberg, S. M.

van Kemenade, F. J.

Snijders, P. J. F.

Boeke, A. J. P.

Meijer, C. J. L. M.

Language :

English

Title :

Implementation of human papillomavirus testing in cervical screening without a concomitant decrease in participation rate.

Publication date :

2006

Journal title :

Journal of Clinical Pathology

ISSN :

0021-9746

eISSN :

1472-4146

Publisher :

BMJ Publishing Group, United Kingdom

Volume :

Issue :

Pages :

1218-20

Peer reviewed :

Peer Reviewed verified by ORBi

Available on ORBi :

since 23 May 2015

Statistics

Number of views

44 (0 by ULiège)

Number of downloads

0 (0 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Walboomers JM, Jacobs MV, Manos MM, et al. Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol 1999;189:12-19.
Bosch FX, Lorincz A, Munoz N, et al. The causal relation between human papillomavirus and cervical cancer. J Clin Pathol 2002;55:244-65.
Cuzick J, Szarewski A, Cubie H, et al. Management of women who test positive for high-risk types of human papillomavirus: the HART study. Lancet 2003;362:1871-6.
Clavel C, Masure M, Bory JP, et al. Human papillomavirus testing in primary screening for the detection of high-grade cervical lesions: a study of 7932 women. Br J Cancer 2001;84:1616-23.
Schiffman M, Khan MJ, Solomon D, et al. A study of the impact of adding HPV types to cervical cancer screening and triage tests. J Natl Cancer Inst 2005;97:147-50.
Kjaer SK, Chackerian B, van den Brule AJ, et al. High-risk human papillomavirus is sexually transmitted: evidence from a follow-up study of virgins starting sexual activity (intercourse). Cancer Epidemiol Biomarkers Prev 2001;10:101-6.
Bulkmans NW, Rozendaal L, Snijders PJ, et al. POBASCAM, a population-based randomized controlled trial for implementation of high-risk HPV testing in cervical screening: design, methods and baseline data of 44,102 women. Int J Cancer 2004;110:94-101.
van Ballegooijen M, Hermens R. Cervical cancer screening in the Netherlands. Eur J Cancer 2000;36:2244-6.
Zielinski GD, Rozendaal L, Meijer CJLM, et al. Cervical cancer screening. HPV test does not influence participation. Medisch Contact 2000;55:430-1.
Maissi E, Marteau TM, Hankins M, et al. Psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: cross sectional questionnaire study. BMJ 2004;328:1293.
Maissi E, Marteau TM, Hankins M, et al. The psychological impact of human papillomavirus testing in women with borderline or mildly dyskaryotic cervical smear test results: 6-month follow-up. Br J Cancer 2005;92:990-4.
Waller J, McCaffery K, Nazroo J, et al. Making sense of information about HPV in cervical screening: a qualitative study. Br J Cancer 2005;92:265-70.
Anhang R, Wright TC Jr, Smock L, et al. Women's desired information about human papillomavirus. Cancer 2004;100:315-20.
Helmerhorst TJ, Meijer O. Cervical cancer should be considered as a rare complication of oncogenic HPV infection rather than a STD. Int J Gynecol Cancer 2002;12:235-6.